CDK4/6 has now gradually become a promising target for HER2‐positive breast cancer, as the cyclin D1/CDK4/6/pRb axis is also a key pathway involved in resistance to HER2‐directed therapy.21 This evidence concerns the gene ERBB2 and breast carcinoma.